Clinical study of adjuvant immuno-cell therapy for pancreatic cancer curatively resectable.

Clinical study of adjuvant immuno-cell therapy for pancreatic cancer curatively resectable. - Clinical study of adjuvant immuno-cell therapy for pancreatic cancer curatively resectable.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000414

Enrollment

Registered

2006-05-02

Start date

2006-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Immuno-cell therapy(CD3-LAK) is done on day0, day14, day28, day42, day56, day70, day84, day98, day112. Gemcitabine is administered on day49, day63, day77, day91, day105, day119, day133, day147, day16

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age:20-75 yers oldNo previous chemotherapy and/or radiotherapy Performance status 0-2 Patients whose life-expectancy is more than 3 months No serious abnormality in bone marrow, liver and/or renal functions

Exclusion criteria

Exclusion criteria: Patients who have: uncontrolled infections, active autoimmune diseases, and serious cardiac disease; who have received continuous systemic steroids; who are pregnant, to be pregnant, or nursing mothers, and whom principle investigator or co-investigator judged to be inappropriate to participate in this study.

Design outcomes

Primary

Measure	Time frame
Relapse-free survival rate of relapse	—

Secondary

Measure	Time frame
Safety Overall survival QOL(KPS) Immunological parameter	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026